Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

340B Drug Pricing Data Should Be Listed On Secure Website, IG Suggests

Executive Summary

The Health Resources & Services Administration is considering developing a website to calculate drug discounts under the 340B program, following a recommendation by the HHS Inspector General
Advertisement

Related Content

340B Drug Discount Program Overcharges Are A Fraction Of Earlier Estimates
340B Drug Discount Program Overcharges Are A Fraction Of Earlier Estimates
340B Drug Discount Program Improves Price Oversight, Participant Database
340B Drug Discount Program Improves Price Oversight, Participant Database
Safety Net Drug Pricing Program Growing Quickly After Eligibility Change
Safety Net Drug Pricing Program Growing Quickly After Eligibility Change
House Bill Would Expand Mandatory Rx Discounts For Uninsured
“Best Price” Exemption For Hospitals Is Test Of Discounts Under Medicare
“Best Price” Exemption For Hospitals Is Test Of Discounts Under Medicare

Topics

Advertisement
UsernamePublicRestriction

Register

PS044265

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel